

Giovanni Brandi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7187544/publications.pdf>

Version: 2024-02-01

210
papers

10,933
citations

50276

46
h-index

34986

98
g-index

211
all docs

211
docs citations

211
times ranked

14711
citing authors

#	ARTICLE	IF	CITATIONS
1	The Key Role of Segmented Filamentous Bacteria in the Coordinated Maturation of Gut Helper T Cell Responses. <i>Immunity</i> , 2009, 31, 677-689.	14.3	1,252
2	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased Î±-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 282-296.	10.7	1,202
3	Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy. <i>Annals of Internal Medicine</i> , 2000, 132, 112.	3.9	1,051
4	Drinking habits as cofactors of risk for alcohol induced liver damage. <i>Gut</i> , 1997, 41, 845-850.	12.1	566
5	Cholangiocarcinoma: Epidemiology and risk factors. <i>Liver International</i> , 2019, 39, 19-31.	3.9	420
6	Molecular Pathways Involved in Colorectal Cancer: Implications for Disease Behavior and Prevention. <i>International Journal of Molecular Sciences</i> , 2013, 14, 16365-16385.	4.1	354
7	Interactions Between Commensal Bacteria and Gut Sensorimotor Function in Health and Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 2560-2568.	0.4	291
8	Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma?. <i>Radiology</i> , 2016, 279, 432-442.	7.3	263
9	Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn's Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 296-305.	1.3	252
10	Intrahepatic Cholangiocarcinoma. <i>Annals of Surgery</i> , 2010, 252, 107-114.	4.2	142
11	Mucosa-associated microbiota dysbiosis in colitis associated cancer. <i>Gut Microbes</i> , 2018, 9, 131-142.	9.8	142
12	High prevalence of celiac disease in Italian general population. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1500-1505.	2.3	138
13	Microbiota, NASH, HCC and the potential role of probiotics. <i>Carcinogenesis</i> , 2017, 38, 231-240.	2.8	125
14	Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review). <i>Oncology Reports</i> , 2010, 23, 1183-92.	2.6	116
15	Hypersensitivity reactions related to oxaliplatin (OHP). <i>British Journal of Cancer</i> , 2003, 89, 477-481.	6.4	113
16	Effect of Vitamin A, C, and E Supplementation on Rectal Cell Proliferation in Patients With Colorectal Adenomas. <i>Journal of the National Cancer Institute</i> , 1992, 84, 47-52.	6.3	93
17	Treatment of hepatic metastases from colorectal cancer: Many doubts, some certainties. <i>Cancer Treatment Reviews</i> , 2006, 32, 214-228.	7.7	91
18	Intestinal microflora and digestive toxicity of irinotecan in mice.. <i>Clinical Cancer Research</i> , 2006, 12, 1299-1307.	7.0	87

#	ARTICLE	IF	CITATIONS
19	Recent advances of immunotherapy for biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 527-536.	3.0	85
20	Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept. <i>Scientific Reports</i> , 2018, 8, 9997.	3.3	84
21	Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. <i>Oncotarget</i> , 2015, 6, 14744-14753.	1.8	80
22	Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2016, 22, 519.	3.3	78
23	Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 441-452.	2.0	78
24	Evolution of the Experimental Models of Cholangiocarcinoma. <i>Cancers</i> , 2020, 12, 2308.	3.7	76
25	Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 343-350.	4.1	75
26	First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1245-1251.	3.0	75
27	Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms. <i>Digestive and Liver Disease</i> , 2016, 48, 231-241.	0.9	74
28	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 235.	7.1	74
29	Urease-Positive Bacteria Other than <i>Helicobacter pylori</i> in Human Gastric Juice and Mucosa. <i>American Journal of Gastroenterology</i> , 2006, 101, 1756-1761.	0.4	71
30	Integrated genomic study of quadruple-WT GIST (KIT/PDGFR α /SDH/RAS pathway wild-type GIST). <i>BMC Cancer</i> , 2014, 14, 685.	2.6	70
31	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100328.	1.7	70
32	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. <i>British Journal of Cancer</i> , 2014, 110, 2165-2169.	6.4	69
33	Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 317-324.	4.1	66
34	Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 371-378.	4.1	65
35	Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study. <i>Oncologist</i> , 2013, 18, 1256-1257.	3.7	64
36	Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait. <i>Immunotherapy</i> , 2021, 13, 637-644.	2.0	63

#	ARTICLE	IF	CITATIONS
37	Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. <i>Angiogenesis</i> , 2012, 15, 275-286.	7.2	61
38	Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy. <i>Future Oncology</i> , 2021, 17, 755-757.	2.4	60
39	Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. <i>British Journal of Cancer</i> , 2016, 115, 297-302.	6.4	58
40	Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. <i>International Journal of Hyperthermia</i> , 2020, 37, 479-485.	2.5	58
41	Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia. <i>Gut</i> , 1997, 41, 330-332.	12.1	57
42	Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow. <i>Anticancer Research</i> , 2020, 40, 3013-3030.	1.1	57
43	Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100337.	1.7	57
44	First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: “And Yet It Moves!” <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100335.	1.7	55
45	Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 156.	8.6	54
46	Changes in the surgical approach to hilar cholangiocarcinoma during an 18-year period in a Western single center. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 329-337.	2.6	53
47	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017, 15, 553-562.	3.4	53
48	Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020, 34, 479-488.	1.3	53
49	Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 547-554.	3.0	52
50	Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look. <i>Cancer Control</i> , 2020, 27, 107327482094804.	1.8	51
51	Asbestos: a hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. <i>Cancer Causes and Control</i> , 2013, 24, 911-918.	1.8	48
52	Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). <i>BMC Genomics</i> , 2015, 16, 892.	2.8	48
53	Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. <i>British Journal of Cancer</i> , 2008, 99, 1729-1734.	6.4	46
54	Ano-rectal Lesions in Patients Taking Suppositories Containing Non-steroidal Anti-inflammatory Drugs (NSAID). <i>Endoscopy</i> , 1990, 22, 146-148.	1.8	45

#	ARTICLE	IF	CITATIONS
55	Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 403-414.	2.5	45
56	Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. <i>Future Oncology</i> , 2020, 16, 2587-2589.	2.4	42
57	Golgi Acidification by NHE7 Regulates Cytosolic pH Homeostasis in Pancreatic Cancer Cells. <i>Cancer Discovery</i> , 2020, 10, 822-835.	9.4	40
58	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , 2021, 124, 1388-1397.	6.4	39
59	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019, 11, 459.	3.7	38
60	Synbiotic yogurt consumption by healthy adults and the elderly: the fate of bifidobacteria and LGG probiotic strain. <i>International Journal of Food Sciences and Nutrition</i> , 2013, 64, 162-168.	2.8	37
61	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. <i>British Journal of Cancer</i> , 2020, 123, 1047-1059.	6.4	37
62	BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 483-485.	3.0	37
63	Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106.	2.8	36
64	Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100354.	1.7	36
65	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
66	Rectal cell proliferation and colorectal cancer risk level in patients with nonfamilial adenomatous polyps of the large bowel. <i>Cancer</i> , 1991, 68, 2451-2454.	4.1	34
67	Colorectal cancer in patients with ulcerative colitis. A prospective cohort study in Italy. <i>Cancer</i> , 1995, 75, 2045-2050.	4.1	33
68	Stereotactic body radiation therapy in cholangiocarcinoma: a systematic review. <i>British Journal of Radiology</i> , 2019, 92, 20180688.	2.2	33
69	Occupational exposure to asbestos and risk of cholangiocarcinoma: a population-based case-control study in four Nordic countries. <i>Occupational and Environmental Medicine</i> , 2018, 75, 191-198.	2.8	31
70	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , 2021, 3, 100215.	4.9	31
71	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 370-379.	7.7	31
72	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. <i>International Journal of Molecular Sciences</i> , 2018, 19, 732.	4.1	29

#	ARTICLE	IF	CITATIONS
73	Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. <i>Cancer Immunology Research</i> , 2019, 7, 751-758.	3.4	29
74	Adjuvant Systemic Chemotherapy After Putative Curative Resection of Colorectal Liver and Lung Metastases. <i>Clinical Colorectal Cancer</i> , 2013, 12, 188-194.	2.3	28
75	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. <i>British Journal of Cancer</i> , 2018, 119, 19-26.	6.4	28
76	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	1.1	26
77	Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2699.	4.1	26
78	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.	3.9	26
79	Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. <i>Cancers</i> , 2022, 14, 2429.	3.7	25
80	Neoadjuvant Treatment in Rectal Cancer: Actual Status. <i>Chemotherapy Research and Practice</i> , 2011, 2011, 1-12.	1.6	24
81	Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. <i>Oncologist</i> , 2016, 21, 600-607.	3.7	24
82	How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis. <i>In Vivo</i> , 2020, 34, 1701-1714.	1.3	23
83	Hacking Pancreatic Cancer: Present and Future of Personalized Medicine. <i>Pharmaceuticals</i> , 2021, 14, 677.	3.8	23
84	Microbiota and prostate cancer. <i>Seminars in Cancer Biology</i> , 2022, 86, 1058-1065.	9.6	23
85	Cancer surveillance in ulcerative colitis: critical analysis of long-term prospective programme. <i>Digestive and Liver Disease</i> , 2002, 34, 339-342.	0.9	21
86	Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 625-630.	2.5	21
87	Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects. <i>Cutaneous and Ocular Toxicology</i> , 2014, 33, 1-6.	1.3	21
88	Non-Coding RNAs as Predictive Biomarkers to Current Treatment in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1547.	4.1	21
89	PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?. <i>Medicines (Basel, Switzerland)</i> , 2020, 7, 54.	1.4	21
90	DNA damage response alterations in gastric cancer: knocking down a new wall. <i>Future Oncology</i> , 2021, 17, 865-868.	2.4	21

#	ARTICLE	IF	CITATIONS
91	Bifidobacterium animalis Protects Intestine from Damage Induced by Zinc Deficiency in Rats. Journal of Nutrition, 1999, 129, 2251-2257.	2.9	20
92	BAP1 in solid tumors. Future Oncology, 2019, 15, 2151-2162.	2.4	20
93	Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study. Anticancer Research, 2019, 39, 3095-3100.	1.1	20
94	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics Journal, 2019, 19, 390-400.	2.0	20
95	Specific Toxicity of Maintenance Olaparib <i>Versus</i> Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis. Anticancer Research, 2020, 40, 597-608.	1.1	20
96	Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFR \pm genotype evaluated by next generation sequencing (NGS). Oncotarget, 2015, 6, 42243-42257.	1.8	20
97	Occurrence of Bifidobacteriaceae in human hypochlorhydria stomach. Microbial Ecology in Health and Disease, 2014, 25, .	3.5	18
98	IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?. Cancer Treatment and Research Communications, 2021, 27, 100356.	1.7	18
99	Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. Cancer Letters, 2004, 208, 193-196.	7.2	17
100	Fluoropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer. International Journal of Cancer, 2020, 147, 3177-3188.	5.1	17
101	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. Clinical Genitourinary Cancer, 2021, 19, 32-40.	1.9	17
102	Port-a-Cath-related complications in 252 patients with solid tissue tumours and the first report of heparin-induced delayed hypersensitivity after Port-a-Cath heparinisation. European Journal of Cancer Care, 2013, 22, 125-132.	1.5	16
103	Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. Anticancer Research, 2017, 37, 955-962.	1.1	16
104	Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma: a case-control study and epidemiological remarks. Scandinavian Journal of Work, Environment and Health, 2020, 46, 609-617.	3.4	16
105	To widen the setting of cancer patients who could benefit from metronomic capecitabine. Cancer Chemotherapy and Pharmacology, 2009, 64, 189-193.	2.3	15
106	Ten-Year Survival after Liver Resection for Breast Metastases: A Single-Center Experience. Digestive Surgery, 2018, 35, 372-380.	1.2	15
107	The (Eternal) Debate on Microwave Ablation <i>Versus</i> Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma. In Vivo, 2020, 34, 3421-3429.	1.3	15
108	Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis. Liver Cancer, 2020, 9, 744-755.	7.7	15

#	ARTICLE	IF	CITATIONS
109	Asbestos and Intrahepatic Cholangiocarcinoma. <i>Cells</i> , 2020, 9, 421.	4.1	15
110	Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 1069-1077.	1.9	14
111	Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. <i>BMC Research Notes</i> , 2015, 8, 325.	1.4	14
112	Heterotopic segmental liver transplantation on splenic vessels after splenectomy with delayed native hepatectomy after graft regeneration: A new technique to enhance liver transplantation. <i>American Journal of Transplantation</i> , 2021, 21, 870-875.	4.7	14
113	Antitumoral Efficacy of the Protease Inhibitor Gabexate Mesilate in Colon Cancer Cells Harboring KRAS, BRAF and PIK3CA Mutations. <i>PLoS ONE</i> , 2012, 7, e41347.	2.5	14
114	Bone Mass and Metabolism in Whipple's Disease: The Role of Hypogonadism. <i>Scandinavian Journal of Gastroenterology</i> , 1998, 33, 1180-1185.	1.5	13
115	Activated NF- κ B in Colorectal Cancer: Predictive or Prognostic Factor?. <i>Journal of Clinical Oncology</i> , 2008, 26, 1388-1389.	1.6	13
116	Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?. <i>Liver International</i> , 2013, 33, 488-493.	3.9	13
117	Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients. <i>Oncology</i> , 2018, 94, 7-11.	1.9	13
118	Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges. <i>Cancer Control</i> , 2020, 27, 107327482098301.	1.8	13
119	Correlation between bromodeoxyuridine labelling and ornithine decarboxylase levels in normal rectal mucosa of patients with colorectal adenoma. <i>Cancer Letters</i> , 1991, 59, 221-224.	7.2	12
120	Effectiveness and cost-effectiveness of peri-operative versus post-operative chemotherapy for resectable colorectal liver metastases. <i>European Journal of Cancer</i> , 2011, 47, 2291-2298.	2.8	12
121	The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation. <i>Scientific Reports</i> , 2017, 7, 11305.	3.3	12
122	Detecting and targeting NTRK gene fusions in cholangiocarcinoma: news and perspectives. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 225-227.	0.7	12
123	Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine. <i>Tumori</i> , 2010, 96, 1028-1030.	1.1	11
124	Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?. <i>Cutaneous and Ocular Toxicology</i> , 2013, 32, 336-338.	1.3	11
125	TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells. <i>Experimental Cell Research</i> , 2018, 373, 44-56.	2.6	11
126	A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2011, 43, 1015-1021.	0.9	10

#	ARTICLE	IF	CITATIONS
127	Safety of hepatic resection for colorectal metastases in the era of neo-adjuvant chemotherapy. <i>Langenbeck's Archives of Surgery</i> , 2012, 397, 397-405.	1.9	10
128	Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 278-284.	3.9	10
129	Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. <i>Liver Cancer</i> , 2020, 9, 440-454.	7.7	10
130	The use of comprehensive complication Index ^Â in pancreatic surgery: a comparison with the Clavien-Dindo system in a high volume center. <i>Hpb</i> , 2021, 23, 618-624.	0.3	10
131	The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9914.	4.1	10
132	Dystrophin deregulation is associated with tumor progression in KIT/PDGFR ^A mutant gastrointestinal stromal tumors. <i>Clinical Sarcoma Research</i> , 2014, 4, 9.	2.3	9
133	Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. <i>Future Oncology</i> , 2017, 13, 1893-1905.	2.4	9
134	Experimental HER2- targeted therapies for biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 389-399.	4.1	9
135	Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100334.	1.7	9
136	Bacteria in Biopsies of Human Hypochloridric Stomach: A Scanning Electron Microscopy Study. <i>Ultrastructural Pathology</i> , 1996, 20, 203-209.	0.9	8
137	Exocrine-Endocrine Pancreatic Cancer and $\hat{\pm}$ -Fetoprotein. <i>Pancreas</i> , 2008, 37, 223-225.	1.1	8
138	Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness. <i>Histopathology</i> , 2015, 66, 244-251.	2.9	8
139	An atlas for clinical target volume definition, including elective nodal irradiation in definitive radiotherapy of biliary cancer. <i>Oncology Letters</i> , 2018, 17, 1784-1790.	1.8	8
140	Combination therapy of dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 506-507.	1.3	8
141	Durable complete response of hepatocellular carcinoma after metronomic capecitabine. <i>Tumori</i> , 2010, 96, 1028-30.	1.1	8
142	Abnormal rectal cell proliferation and p52p35 protein expression in patients with ulcerative colitis. <i>Cancer Letters</i> , 1993, 73, 23-28.	7.2	7
143	HIV Enteropathy: Undescribed Ultrastructural Changes of Duodenal Mucosa and Their Regression After Triple Antiviral Therapy. A Case Report. <i>Digestive Diseases and Sciences</i> , 2005, 50, 617-622.	2.3	7
144	Fulminant Hepatitis in a Patient with Hepatocellular Carcinoma Related to Nonalcoholic Steatohepatitis Treated with Sorafenib. <i>Tumori</i> , 2015, 101, e46-e48.	1.1	7

#	ARTICLE	IF	CITATIONS
145	Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms. <i>Journal of Chemotherapy</i> , 2018, 30, 53-58.	1.5	7
146	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	1.1	7
147	Nivolumab: an investigational agent for the treatment of biliary tract cancer. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 325-332.	4.1	7
148	FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 567-574.	3.0	7
149	Identifying ethical values for guiding triage decisions during the COVID-19 pandemic: an Italian ethical committee perspective using Delphi methodology. <i>BMJ Open</i> , 2021, 11, e043239.	1.9	7
150	Cold single-strand conformation polymorphism analysis: Optimization for detection of APC gene mutations in patients with familial adenomatous polyposis. <i>International Journal of Molecular Medicine</i> , 2001, 8, 567-72.	4.0	6
151	Venous Thromboembolism and Port-Related Thrombosis in Metastatic Colorectal Cancer Patients: A Monocenter Experience. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2010, 37, 30-34.	0.3	6
152	Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer. <i>Pancreas</i> , 2016, 45, 714-719.	1.1	6
153	TRK inhibition in cholangiocarcinoma: Trying to teach an old dog new tricks. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100351.	1.7	6
154	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 289-298.	1.3	6
155	In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)" <i>Oncologist</i> , 2021, 26, e902-e902.	3.7	6
156	Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future. <i>Current Oncology</i> , 2022, 29, 551-564.	2.2	6
157	Unresectable perihilar cholangiocarcinoma: multimodal palliative treatment. <i>Anticancer Research</i> , 2013, 33, 2747-53.	1.1	6
158	Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. <i>International Journal of Colorectal Disease</i> , 2004, 19, 599-602.	2.2	5
159	Durable Complete Response to Frontline Docetaxel in an Advanced Prostate Cancer Patient with Favourable CYP1B1 Isoforms: Suggestion for Changing Paradigms?. <i>European Urology</i> , 2008, 54, 938-941.	1.9	5
160	Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer" <i>Oncologist</i> , 2020, 25, e1818-e1818.	3.7	5
161	Long-term survival of two patients with recurrent pancreatic acinar cell carcinoma treated with radiofrequency ablation: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 1241-1250.	0.8	5
162	Impact of Surgery on the Development of Duodenal Cancer in Patients with Familial Adenomatous Polyposis. <i>Diseases of the Colon and Rectum</i> , 2006, 49, 1860-1866.	1.3	4

#	ARTICLE	IF	CITATIONS
163	Irinotecan toxicity: genes or intestinal microflora?. <i>British Journal of Cancer</i> , 2009, 100, 1017-1017.	6.4	4
164	Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases. <i>Cancer Communications</i> , 2018, 38, 1-7.	9.2	4
165	Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster. <i>BMC Medical Genetics</i> , 2020, 21, 225.	2.1	4
166	Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements. <i>Frontiers in Pharmacology</i> , 2020, 11, 559996.	3.5	4
167	A foreword on biliary tract cancers: emerging treatments, drug targets, and fundamental knowledge gaps. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 279-279.	4.1	4
168	Nanotechnology-Related Environment, Health, and Safety Research. <i>Environmental Health Perspectives</i> , 2009, 117, .	6.0	3
169	Antiprotease Strategy in Pancreatic Cancer Treatment. <i>Pancreas</i> , 2014, 43, 53-63.	1.1	3
170	A Preliminary Communication: Ongoing Study on HOXA10 Methylation Profile of Endometriosis Patients with Infertility. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2016, 8, 106-110.	0.5	3
171	Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review. <i>Molecular and Clinical Oncology</i> , 2021, 15, 152.	1.0	3
172	Second-line liposomal irinotecan plus fluorouracil and leucovorin in metastatic biliary tract cancer. <i>Lancet Oncology</i> , The, 2022, 23, e11.	10.7	3
173	Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link. <i>Annals of Global Health</i> , 2022, 88, .	2.0	3
174	Re: Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1278-1278.	6.3	2
175	Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors. <i>Gastroenterology</i> , 2012, 143, e20-e21.	1.3	2
176	Second-line chemotherapy in advanced biliary cancer: the present now will later be past. <i>Annals of Oncology</i> , 2014, 25, 2443-2444.	1.2	2
177	Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. <i>Future Oncology</i> , 2019, 15, 563-565.	2.4	2
178	Second-line FOLFOX chemotherapy for advanced biliary tract cancer. <i>Lancet Oncology</i> , The, 2021, 22, e285.	10.7	2
179	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. <i>Acta Oncologica</i> , 2021, 60, 1317-1324.	1.8	2
180	The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma. <i>Anti-Cancer Drugs</i> , 2022, 33, e781-e783.	1.4	2

#	ARTICLE	IF	CITATIONS
181	Toward personalized therapy for cholangiocarcinoma: new insights and challenges. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1241-1243.	3.0	2
182	Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report. Medicines (Basel, Switzerland), 2021, 8, 5.	1.4	2
183	Extrahepatic Feeding of HCC Limits the Use of TACE? Evidences from Literature and Clinical Experience. Journal of Cancer Therapy, 2013, 04, 413-419.	0.4	2
184	Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report. World Journal of Gastrointestinal Oncology, 2020, 12, 1456-1463.	2.0	2
185	Author's reply. Scandinavian Journal of Work, Environment and Health, 2021, 47, 87-89.	3.4	2
186	Risk of Duodenal Adenomas in Familial Adenomatous Polyposis to Progress Toward Advanced Neoplastic Disease. Journal of Clinical Oncology, 2004, 22, 3835-3836.	1.6	1
187	Breast carcinoma presenting as linitis plastica. Digestive and Liver Disease, 2010, 42, 306.	0.9	1
188	Chemotherapy followed by chemoradiotherapy in locally advanced pancreatic cancer: A literature review and report of two cases. Oncology Letters, 2011, 2, 195-200.	1.8	1
189	Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention. Hepatology, 2017, 65, 1075-1076.	7.3	1
190	An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone. Anti-Cancer Drugs, 2019, 30, 428-430.	1.4	1
191	Is the Strongest Level of Medical Evidence Always Required for Guidelines Recommendations?. Liver Cancer, 2021, 10, 1-2.	7.7	1
192	Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma?. Translational Cancer Research, 2016, 5, S450-S453.	1.0	1
193	Adjuvant treatment in biliary tract cancer. Translational Cancer Research, 2019, 8, S289-S296.	1.0	1
194	Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. Expert Review of Precision Medicine and Drug Development, 2022, 7, 1-3.	0.7	1
195	Measurement of rectal cell proliferation by bromodeoxyuridine uptake and proliferating cell nuclear antigen (PCNA). European Journal of Cancer Prevention, 1993, 2, 30.	1.3	0
196	Colite ulcéreuse chronique et cancer colorectal. Acta Endoscopica, 1995, 25, 71-80.	0.0	0
197	Familial adenomatous polyposis (FAP): Dysplasia and pouchitis of the pouch after ileal pouch-anal anastomosis (IPAA). Gastroenterology, 2000, 118, A1119.	1.3	0
198	Occupational exposure to asbestos and cholangiocarcinoma: findings from an explorative case-control analysis. Occupational and Environmental Medicine, 2011, 68, A21-A21.	2.8	0

#	ARTICLE	IF	CITATIONS
199	In Reply. <i>Oncologist</i> , 2016, 21, e5-e6.	3.7	0
200	Cholangiocarcinoma: from risk to prevention?. <i>Translational Gastroenterology and Hepatology</i> , 2016, 1, 53-53.	3.0	0
201	The best overall response to the first-line but not to the second-line treatment correlates with outcome of metastatic right-sided and left-sided colon cancer. <i>Annals of Oncology</i> , 2017, 28, iii105-iii106.	1.2	0
202	Surveillance improves survival of intrahepatic cholangiocarcinoma arisen in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S389.	3.7	0
203	In Vitro and In Vivo Model Systems of Cholangiocarcinoma. , 2021, , 471-494.		0
204	Ivosidenib in IDH-mutant cholangiocarcinoma: where do we stand?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 217-224.	0.7	0
205	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	1.3	0
206	Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (HCC) with orbital metastases: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 8474-8478.	1.2	0
207	Radiofrequency ablation for intrahepatic cholangiocarcinoma: a tool upon the path of integrative modalities?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1-2.	3.0	0
208	Role of nonalcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its role in patients's prognosis: A case-control study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 224-224.	1.6	0
209	Hot topics in cholangiocarcinoma. <i>Translational Cancer Research</i> , 2019, 8, S219-S222.	1.0	0
210	FGFR Inhibitors in Cholangiocarcinoma: A Real-World Experience at a Tertiary Center. <i>JCO Precision Oncology</i> , 2022, 6, e2100511.	3.0	0